Literature DB >> 22532547

Cerebral vasculopathy in children with neurofibromatosis type 1.

Partha S Ghosh1, A David Rothner, Todd M Emch, Neil R Friedman, Manikum Moodley.   

Abstract

Cerebral vasculopathy is an important but underrecognized complication of neurofibromatosis type 1. Over a 10-year period, we retrospectively assessed the prevalence, clinical manifestations, management, and outcome of cerebral vasculopathy in children with neurofibromatosis type 1. Magnetic resonance imaging (MRI) of the brain was performed on 78% of the patients (312/398) of which 46% (143/312) had magnetic resonance angiography of the intracranial arteries; 4.8% (15/312) had cerebral vasculopathy. Approximately half were asymptomatic at presentation; none had neurologic deficits. Cerebral vasculopathy included moyamoya changes (7) and stenosis/occlusion of major intracranial arteries (8). On follow-up (mean 4 years), 2 patients developed radiologic progression; 1 was treated with aspirin alone, whereas another underwent revascularization surgery. Although cerebral vasculopathy in neurofibromatosis type 1 may be asymptomatic at presentation, there may be radiologic and clinical progression leading to morbidity and mortality. Magnetic resonance angiography should be considered with brain MRI for early detection and timely intervention of cerebral vasculopathy.

Entities:  

Mesh:

Year:  2012        PMID: 22532547     DOI: 10.1177/0883073812441059

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  14 in total

Review 1.  Neuroimaging of phakomatoses: overview and advances.

Authors:  Gilbert Vézina
Journal:  Pediatr Radiol       Date:  2015-09-07

2.  Cerebellar Hypoplasia and Dysmorphia in Neurofibromatosis Type 1.

Authors:  Sandra P Toelle; Andrea Poretti; Peter Weber; Tatjana Seute; Jacoline E C Bromberg; Ianina Scheer; Eugen Boltshauser
Journal:  Cerebellum       Date:  2015-12       Impact factor: 3.847

3.  When and why is surgical revascularization indicated for the treatment of moyamoya syndrome in patients with RASopathies? A systematic review of the literature and a single institute experience.

Authors:  Marcello Scala; Pietro Fiaschi; Valeria Capra; Maria Luisa Garrè; Domenico Tortora; Marcello Ravegnani; Marco Pavanello
Journal:  Childs Nerv Syst       Date:  2018-05-24       Impact factor: 1.475

4.  Diffusion tensor imaging of neurofibromatosis bright objects in children with neurofibromatosis type 1.

Authors:  Gulhan Ertan; Elcin Zan; David M Yousem; Can Ceritoglu; Aylin Tekes; Andrea Poretti; Thierry A G M Huisman
Journal:  Neuroradiol J       Date:  2014-09-25

Review 5.  Abusive head trauma: neuroimaging mimics and diagnostic complexities.

Authors:  Jai Sidpra; Sahil Chhabda; Adam J Oates; Aashim Bhatia; Susan I Blaser; Kshitij Mankad
Journal:  Pediatr Radiol       Date:  2021-05-17

6.  Endovascular treatment of basilar artery stenosis due to cerebral vasculopathy related to neurofibromatosis (NF1).

Authors:  Anand Alurkar; Lakshmi Sudha Prasanna Karanam; Sagar Oak
Journal:  J Vasc Interv Neurol       Date:  2014-05

Review 7.  Cerebrovascular stenosis in neurofibromatosis type 1 and utility of magnetic resonance angiography: our experience and literature review.

Authors:  Felice D'Arco; Alessandra D'Amico; Ferdinando Caranci; Nilde Di Paolo; Daniela Melis; Arturo Brunetti
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

Review 8.  Neurovascular manifestations of connective-tissue diseases: A review.

Authors:  Sarasa T Kim; Waleed Brinjikji; Giuseppe Lanzino; David F Kallmes
Journal:  Interv Neuroradiol       Date:  2016-08-10       Impact factor: 1.610

Review 9.  Moyamoya Syndrome: A Window of Moyamoya Disease.

Authors:  Ji Hoon Phi; Kyu-Chang Wang; Ji Yeoun Lee; Seung-Ki Kim
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

10.  Moyamoya syndrome and neurofibromatosis type 1.

Authors:  Euthymia Vargiami; Evdoxia Sapountzi; Dimitris Samakovitis; Spyros Batzios; Maria Kyriazi; Athanasia Anastasiou; Dimitrios I Zafeiriou
Journal:  Ital J Pediatr       Date:  2014-06-21       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.